Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M66,723Revenue $M8,264Net Margin (%)11.2Z-Score2.6
Enterprise Value $M80,344EPS $2.7Operating Margin %24.8F-Score6
P/E(ttm))83.8Cash Flow Per Share $4.9Pre-tax Margin (%)13.4Higher ROA y-yY
Price/Book13.810-y EBITDA Growth Rate %10.5Quick Ratio1.2Cash flow > EarningsY
Price/Sales8.25-y EBITDA Growth Rate %55.9Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %148ROA % (ttm)3.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)18.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M334ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 198.4632%Reduce -6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 198.4632%Reduce -24.90%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 198.4632%Reduce -18.50%1,378,606
VRXAndreas Halvorsen 2014-12-31 Reduce-0.47%$113.56 - $146.39
($134.66)
$ 198.4632%Reduce -8.94%9,077,007
VRXJeff Ubben 2014-12-31 Add0.41%$113.56 - $146.39
($134.66)
$ 198.4632%Add 2.43%19,383,877
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 198.4632%New holding295,632
VRXLee Ainslie 2014-12-31 Reduce-0.2%$113.56 - $146.39
($134.66)
$ 198.4632%Reduce -4.12%2,423,766
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 198.4632%Reduce -1.19%1,794,227
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 198.4632%Reduce -0.47%34,331,973
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 198.4640%Add 8.86%6,586,582
VRXAndreas Halvorsen 2014-09-30 Reduce-1.02%$106.73 - $130.26
($118.9)
$ 198.4640%Reduce -15.75%9,967,690
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 198.4640%Add 12.40%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 198.4640%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 198.4640%Add 8.89%10,985,940
VRXLee Ainslie 2014-09-30 Reduce-0.18%$106.73 - $130.26
($118.9)
$ 198.4640%Reduce -3.70%2,527,896
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 198.4640%Add 32.73%626,748
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 198.4640%Add 11.91%3,529,237
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 198.4640%Add 0.57%34,494,015
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 198.4640%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 198.4636%Add 8.19%6,050,442
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-03-02Sell90,939$200.01-0.77view
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4823.67view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0641.7view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.7336.18view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7336.18view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.9521.05view
Farmer, RonDirector 2014-11-24Buy1,000$163.9521.05view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.2539.51view
Chai-Onn, Robert RoswellSenior Officer 2014-06-23Sell10,203$121.763.07view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.763.07view

Press Releases about VRX :

    Quarterly/Annual Reports about VRX:

    News about VRX:

    Articles On GuruFocus.com
    Pershing Square Holdings: First Annual Report Mar 25 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 
    Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
    Ruane, Cunniff & Goldfarb’s Sequoia Fund Q4 2014 Shareholder Letter Mar 16 2015 
    Ruane Cunniff Sells Portions of Five of its Top 10 Stakes Mar 13 2015 
    Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
    How Good is Your Argument? Feb 16 2015 
    Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 


    More From Other Websites
    Transaction Basics of the Life Time Fitness Merger Mar 26 2015
    FactSet: U.S. M&A Activity Dips in February as Private Equity Surges Mar 26 2015
    Kraft Foods And The Rise Of Wall Street's Buy And Hold Kingpins Mar 26 2015
    Actavis takes 'specialty pharma' route to health Mar 26 2015
    With New Valeant Pharmaceuticals Intl Inc (VRX) Stake, Bill Ackman Maintains Large Exposure to... Mar 26 2015
    Ackman Boosts Stake In Valeant; Still Appears To Be Passive Mar 25 2015
    On Zero-Based Budgeting, Activists at Knee of 3G Mar 25 2015
    Valeant Pharmaceuticals (VRX): An Off-the-Radar Potential Winner - Tale of the Tape Mar 25 2015
    Salix had a $13B offer on the table before accounting problems crashed share price Mar 24 2015
    Edeleman, iShares Launch Exponential Technologies ETF Mar 24 2015
    Edelman, iShares Launch Exponential Technologies ETF Mar 24 2015
    Talking Allergan at Tulane: a 'Horse Choker,' the 'Shamarendum' and More Mar 24 2015
    Can Valeant Pharmaceuticals (VRX) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape Mar 24 2015
    The Federal Reserve: Patient No More? Mar 23 2015
    Eminence Capital Downs Position in Valeant Pharmaceuticals Mar 23 2015
    Surging Earnings Estimates Signal Good News for Valeant Pharmaceuticals (VRX) - Tale of the Tape Mar 23 2015
    Actavis' Wide-Moat Transformation Offers Shareholder Rewards Mar 23 2015
    Point72 Asset Management’s New Position in Gilead Sciences Mar 23 2015
    Dovish Fed stance lifts US stocks near records Mar 20 2015
    Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares Mar 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK